We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

113 hedge funds and large institutions have $623M invested in Relmada Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

97% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $13.4M

95% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 21

33% more capital invested

Capital invested by funds: $467M → $623M (+$156M)

16% more funds holding

Funds holding: 97 → 113 (+16)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

39.73% less ownership

Funds ownership: 118.31% → 78.58% (-40%)

Holders
113
Holders Change
+16
Holders Change %
+16.49%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
29
Increased
41
Reduced
21
Closed
13
Calls
$26.4M
Puts
$13.4M
Net Calls
+$13M
Net Calls Change
+$10.4M

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$21M
2
Citadel Advisors
Citadel Advisors
Florida
+$13.3M
3
BlackRock
BlackRock
New York
+$11.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.57M
5
RI
RTW Investments
New York
+$7.31M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$16.5M
2
LGM
Logos Global Management
California
-$9.01M
3
Morgan Stanley
Morgan Stanley
New York
-$6.35M
4
Millennium Management
Millennium Management
New York
-$5.67M
5
SFM
Sphera Funds Management
Israel
-$3.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nisa Investment Advisors
101
Nisa Investment Advisors
Missouri
$6K -$101K -4,863 -96%
TRCT
102
Tower Research Capital (TRC)
New York
$6K -$21.1K -1,019 -83%
S
103
SignatureFD
Georgia
$6K +$2.23K +108 +98%
Fidelity Investments
104
Fidelity Investments
Massachusetts
$6K +$4.4K +213 +1,065%
ACM
105
Aquatic Capital Management
Illinois
$3K -$18.6K -900 -90%
Daiwa Securities Group
106
Daiwa Securities Group
Japan
$2K +$1.07K +52 +168%
CAPTRUST Financial Advisors
107
CAPTRUST Financial Advisors
North Carolina
$2K +$1.2K +58 New
Carson Wealth (CWM LLC)
108
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
QCG
109
Quadrant Capital Group
Ohio
$1K – – –
SOW
110
State of Wyoming
Wyoming
$1K +$662 +32 New
Macquarie Group
111
Macquarie Group
Australia
$3 – – –
APM
112
Avidity Partners Management
Texas
– -$16.5M -731,536 Closed
LGM
113
Logos Global Management
California
– -$9.01M -400,000 Closed
Norges Bank
114
Norges Bank
Norway
– -$2.22M -98,500 Closed
E
115
Ergoteles
New York
– -$2.06M -91,500 Closed
TCM
116
Tang Capital Management
California
– -$1.33M -59,122 Closed
SSA
117
Schonfeld Strategic Advisors
New York
– -$1.24M -54,800 Closed
Susquehanna International Group
118
Susquehanna International Group
Pennsylvania
– -$481K -23,255 Closed
GCP
119
GSA Capital Partners
United Kingdom
– -$393K -17,429 Closed
GCM
120
Ghisallo Capital Management
Massachusetts
– -$338K -15,000 Closed
Renaissance Technologies
121
Renaissance Technologies
New York
– -$324K -14,400 Closed
Simplex Trading
122
Simplex Trading
Illinois
– -$189K -9,143 Closed
DMKJ
123
David M. Knott Jr
– -$135K -6,000 Closed
MPWT
124
MassMutual Private Wealth & Trust
Connecticut
– -$1K -28 Closed
PNC Financial Services Group
125
PNC Financial Services Group
Pennsylvania
– +$269 +13 New
1 2 3 4
5

RLMD Hedge Fund Activity: Q1 2022 in Review

113 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2022, worth a combined $623M — up 33% from $467M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new RLMD positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 21 trimmed.

The largest buyer was Cowen and Company, adding an estimated $21M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $16.5M sold.

  • 113 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2022, up from 97 in Q4 2021.
  • Funds reported $623M of Relmada Therapeutics stock for Q1 2022, up 33% quarter-over-quarter.
  • 29 funds opened new Relmada Therapeutics positions in Q1 2022 and 13 closed out, a net change of +16 holders.
  • The largest Relmada Therapeutics buyer in Q1 2022 was Cowen and Company, an estimated $21M added.
  • The largest Relmada Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $16.5M sold.

Based on aggregated 13F filings for Q1 2022.